Menu
Partner Andrew Wasson will be speaking at the 8th Annual Summit on Life Sciences IP Due Diligence in Boston. This year’s program will focus on due diligence red flags, international considerations, and the broad scope of IP protections including a deep dive on trade secrets.
His session is titled, “Red Flags Part 3 – Flagging Patents in Danger of Orange Book Delisting: The Value of the Patent, the Portfolio, and the Deal.” Andrew will discuss the implications of Federal Circuit’s decision in Teva v. Amneal, FTC’s post-Teva activity, and how Orange Book listability is addressed during due diligence.
The conference will take place December 3-4 in Boston, with Andrew’s session scheduled on December 4 at 3:15 PM. To register for this event and for additional info, click here.